Development and validation of response criteria in rheumatoid arthritis: Steps towards an international consensus on prognostic markers

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 2, 1996, Pages 4-7

  Van Riel, P L C M ^a   Van Gestel, A M ^a   Van De Putte, L B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Prognostic markers; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS;

EID: 0029797663     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_2.4     Document Type: Article

References (25)

1. van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 1988;17:284-92.
2. van de Heijde DMFM, van Riel PLCM, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31:519-25.
3. van Riel PLCM. Provisional guidelines for measuring disease activity in RA clinical trials. Editorial. Br J Rheumatol 1992;31:793-4.
4. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
5. van der Heijde DMFM, van't Hof MA, van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'. Ann Rheum Dis 1990;49:916-20.
6. van der Heijde DMFM, van't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
7. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
8. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
9. Pincus T, Callahan LF, Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict long-term morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992;19:1051-7.
10. van de Putte LBA, van Riel PLCM. Do disease-modifying antirheumatic drugs actually modify disease course in rheumatoid arthritis? Clin Immunother 1994;1:318-22.
11. van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
12. Tugwell P, Baker P. Improvement and sustained improvement in function. ILAR Bull 1994;2:22-3.
13. Paulus HE, Egger MJ, Ward JR, Williams HJ, CSSRD Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
14. Boers M. Low-dose prednisone in rheumatoid arthritis patients: placebo treatment? (Letter) Arthritis Rheum 1991;34:501-2.
15. Furst DE. Considerations on measuring decreased inflammatory synovitis. ILAR Bull 1994;2:17-21.
16. Felson DT. American College of Rheumatology (ACR) preliminary criteria for improvement in rheumatoid arthritis (RA) trials. Arthritis Rheum 1994;37:S195 (abstract).
17. van Riel PLCM, van de Putte LBA. DC-ART: what proportion of response constitutes a positive response? J Rheumatol 1994;21(suppl. 41):54-6.
18. van der Heijde DMFM, van't Hof MA, van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
19. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. The development and validation of EULAR response criteria in rheumatoid arthritis. A comparison with ACR and WHO/ILAR response criteria. Arthritis Rheum 1996;39:34-40.
20. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Validity of newly developed response criteria for rheumatoid arthritis. Clin Rheumatol 1995;14:263 (abstract).
21. van Riel PLCM, Reekers P, van de Putte LBA, Gribnau FWJ. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens 1983; 22:194-9.
22. Nuver-Zwart HH, van Riel PLCM, van de Putte LBA, Gribnau FWJ. A double-blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis. Ann Rheum Dis 1989;48:389-95.
23. van der Heijde DMFM, van Riel PLCM, Nuver-Zwart HH, Gribnau FWJ, van de Putte LBA. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; i:1036-8.
24. van Riel PLCM, van de Putte LBA. Clinical assessment and clinical trials in rheumatoid arthritis. Curr Opin Rheumatol 1994;6:132-9.
25. Prevoo MLL, van Riel PLCM, van't Hof MA et al. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993;32:589-94.